Skip to content

Released May 4, 2023, before the open

10-Q filed May 4, 2023, 34 days after period end · 0001558370-23-008132

Q1 2023 · 10-Q
Revenue$9.59M−40.4% vs Q1 2022+11.3% vs Q4 2022
Net Income-$3.13MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.05N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$2,459,000N/M
Operating Cash Flow-$2,998,000N/M
Free Cash Flowderived-$3,246,000N/M
Margins · derived
Operating margin-25.6%−14.0 pt vs Q1 2022
Net margin-32.7%−18.4 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$9.59M$16.09M$11.32M$21.65M
Net Income-$3.13M-$2.29M-$5.48M$1.67M
EPS Diluted-$0.05-$0.05-$0.14$0.10

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR